ES2189002T3 - Procedimiento in vitro y utilizacion de composiciones farmaceuticas para el tratamiento de celulas ciliares del oido interno. - Google Patents

Procedimiento in vitro y utilizacion de composiciones farmaceuticas para el tratamiento de celulas ciliares del oido interno.

Info

Publication number
ES2189002T3
ES2189002T3 ES97949346T ES97949346T ES2189002T3 ES 2189002 T3 ES2189002 T3 ES 2189002T3 ES 97949346 T ES97949346 T ES 97949346T ES 97949346 T ES97949346 T ES 97949346T ES 2189002 T3 ES2189002 T3 ES 2189002T3
Authority
ES
Spain
Prior art keywords
internal ear
treatment
pharmaceutical compositions
vitro procedure
ciliary cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES97949346T
Other languages
English (en)
Inventor
Wei-Qiang Gao
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Application granted granted Critical
Publication of ES2189002T3 publication Critical patent/ES2189002T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1841—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

LA PRESENTE INVENCION SE REFIERE A UNAS COMPOSICIONES, UNOS PROCEDIMIENTOS Y UNOS DISPOSITIVOS QUE FAVORECEN O REFUERZAN EL CRECIMIENTO, LA PROLIFERACION O LA REGENERACION DE LOS TEJIDOS DEL OIDO INTERNO Y EN PARTICULAR DE LOS PELOS AUDITIVOS DEL OIDO INTERNO. ESTA INVENCION SE REFIERE TAMBIEN A UNAS COMPOSICIONES Y UNOS PROCEDIMIENTOS DE PROFILAXIS Y DE TRATAMIENTO DE LOS MAMIFEROS AFECTADOS POR TRASTORNOS DEL OIDO INTERNO O DE ESTADOS VINCULADOS EN PARTICULAR A UNOS DEFECTOS DE AUDICION DEBIDOS A LESIONES DE DICHOS PELOS O A SU PERDIDA O SU DEGENERACION, MEDIANTE ADMINISTRACION DE UNA DOSIS CON EFECTO TERAPEUTICO DE IGF - 1, O DE FGF - 2, O DE SUS AGONISTAS, SOLOS O COMBINADOS.
ES97949346T 1996-11-01 1997-10-28 Procedimiento in vitro y utilizacion de composiciones farmaceuticas para el tratamiento de celulas ciliares del oido interno. Expired - Lifetime ES2189002T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2953696P 1996-11-01 1996-11-01
US08/743,267 US6593290B1 (en) 1996-11-01 1996-11-04 Treatment of inner ear hair cells

Publications (1)

Publication Number Publication Date
ES2189002T3 true ES2189002T3 (es) 2003-07-01

Family

ID=26705049

Family Applications (1)

Application Number Title Priority Date Filing Date
ES97949346T Expired - Lifetime ES2189002T3 (es) 1996-11-01 1997-10-28 Procedimiento in vitro y utilizacion de composiciones farmaceuticas para el tratamiento de celulas ciliares del oido interno.

Country Status (15)

Country Link
US (1) US6593290B1 (es)
EP (1) EP0948349B1 (es)
JP (1) JP4191252B2 (es)
CN (1) CN1313147C (es)
AR (1) AR009603A1 (es)
AT (1) ATE229815T1 (es)
AU (1) AU724988B2 (es)
BR (1) BR9712468A (es)
CA (1) CA2268331C (es)
DE (1) DE69718053T2 (es)
DK (1) DK0948349T3 (es)
ES (1) ES2189002T3 (es)
IL (2) IL129381A0 (es)
WO (1) WO1998019700A1 (es)
ZA (1) ZA979814B (es)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8039026B1 (en) 1997-07-28 2011-10-18 Johnson & Johnson Consumer Companies, Inc Methods for treating skin pigmentation
US8093293B2 (en) 1998-07-06 2012-01-10 Johnson & Johnson Consumer Companies, Inc. Methods for treating skin conditions
US8106094B2 (en) 1998-07-06 2012-01-31 Johnson & Johnson Consumer Companies, Inc. Compositions and methods for treating skin conditions
AUPP785098A0 (en) 1998-12-21 1999-01-21 Victor Chang Cardiac Research Institute, The Treatment of heart disease
US6635249B1 (en) 1999-04-23 2003-10-21 Cenes Pharmaceuticals, Inc. Methods for treating congestive heart failure
EP2325198A1 (en) 1999-06-01 2011-05-25 Baylor College Of Medicine Compositions and methods for the therapeutic use of an atonal-associated sequence
US7053200B1 (en) 1999-06-01 2006-05-30 Baylor College Of Medicine Compositions and methods for the therapeutic use of an atonal-associated sequence for deafness, osteoarthritis, and abnormal cell proliferation
AU4885500A (en) * 1999-07-27 2001-02-01 Johnson & Johnson Consumer Companies, Inc. Reducing hair growth, hair follicle and hair shaft size and hair pigmentation
US7309688B2 (en) 2000-10-27 2007-12-18 Johnson & Johnson Consumer Companies Topical anti-cancer compositions and methods of use thereof
EP1307542A2 (en) * 2000-07-11 2003-05-07 Sound Pharmaceuticals Incorporated Stimulation of cellular regeneration and differentiation in the inner ear
US8431550B2 (en) 2000-10-27 2013-04-30 Johnson & Johnson Consumer Companies, Inc. Topical anti-cancer compositions and methods of use thereof
US7192615B2 (en) 2001-02-28 2007-03-20 J&J Consumer Companies, Inc. Compositions containing legume products
AU2002304965A1 (en) * 2002-05-24 2003-12-12 Zensun (Shanghai) Sci-Tech.Ltd Neuregulin based methods and compositions for treating viral myocarditis and dilated cardiomyopathy
AU2003268741B2 (en) 2002-10-02 2009-06-11 Anges Mg, Inc. Drug for auditory dysfunction
PL1606409T3 (pl) 2003-03-19 2011-02-28 Biogen Ma Inc Białko wiążące receptor Nogo
PT1776136E (pt) 2004-06-24 2012-12-05 Biogen Idec Inc Tratamento de estados que envolvem desmielinização
US20070082858A1 (en) * 2004-12-21 2007-04-12 Oregon Health & Science University Methods and compositions for the prevention of toxic side effects of aminoglycoside medications
SI1904104T1 (sl) 2005-07-08 2013-12-31 Biogen Idec Ma Inc. Protitelesa SP35 in njihova uporaba
US20070213264A1 (en) 2005-12-02 2007-09-13 Mingdong Zhou Neuregulin variants and methods of screening and using thereof
CA2841386A1 (en) 2005-12-30 2007-07-12 Zensun (Shanghai) Science & Technology Limited Extended release of neuregulin for improved cardiac function
WO2009061500A1 (en) * 2007-11-08 2009-05-14 Biogen Idec Ma Inc. Use of lingo-4 antagonists in the treatment of conditions involving demyelination
EP2315779A2 (en) 2008-07-09 2011-05-04 Biogen Idec MA Inc. Compositions comprising antibodies to lingo or fragments thereof
US8496957B2 (en) 2008-07-21 2013-07-30 Otonomy, Inc Controlled release auris sensory cell modulator compositions and methods for the treatment of otic disorders
US8447409B2 (en) * 2008-10-15 2013-05-21 Cochlear Limited Electroneural interface for a medical implant
US7934558B2 (en) 2009-03-13 2011-05-03 Halliburton Energy Services, Inc. System and method for dynamically adjusting the center of gravity of a perforating apparatus
WO2013053076A1 (en) 2011-10-10 2013-04-18 Zensun （Shanghai）Science & Technology Limited Compositions and methods for treating heart failure
US9796780B2 (en) 2012-05-14 2017-10-24 Biogen Ma Inc. LINGO-2 antagonists for treatment of conditions involving motor neurons
BR112015023261A2 (pt) 2013-03-14 2017-07-18 Massachusetts Inst Technology composições e métodos para expansão e cultura de células-tronco epiteliais
CN107073042A (zh) 2014-09-03 2017-08-18 布里格海姆妇女医院公司 用于产生内耳毛细胞来治疗听力损失的组合物、系统和方法
TWI710635B (zh) 2014-10-09 2020-11-21 美商珍維克公司 編碼人類無調同源物-1(hath1)之腺病毒載體
WO2016112270A1 (en) 2015-01-08 2016-07-14 Biogen Ma Inc. Lingo-1 antagonists and uses for treatment of demyelinating disorders
CA3010610A1 (en) 2016-01-08 2017-07-13 The Brigham And Women's Hospital, Inc. Production of differentiated enteroendocrine cells and insulin producing cells
US11260130B2 (en) 2016-03-02 2022-03-01 Frequency Therapeutics, Inc. Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using a GSK3 inhibitor: IV
US10213511B2 (en) 2016-03-02 2019-02-26 Frequency Therapeutics, Inc. Thermoreversible compositions for administration of therapeutic agents
US10201540B2 (en) 2016-03-02 2019-02-12 Frequency Therapeutics, Inc. Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using GSK3 inhibitors: I
CN109562140B (zh) * 2016-06-03 2023-01-03 霍夫耳科研究所 用于内耳感觉毛细胞再生/替换的联合疗法
CN106075392B (zh) * 2016-07-18 2020-07-07 滨州医学院 促红细胞生成素衍生物在听力保护上的应用
AU2017386417B2 (en) 2016-12-30 2022-07-14 Frequency Therapeutics, Inc. 1H-pyrrole-2,5-dione compounds and methods of using them to induce self-renewal of stem/progenitor supporting cells
WO2020037323A1 (en) 2018-08-17 2020-02-20 Frequency Therapeutics, Inc. Compositions and methods for generating hair cells by upregulating jag-1
WO2020037326A1 (en) 2018-08-17 2020-02-20 Frequency Therapeutics, Inc. Compositions and methods for generating hair cells by downregulating foxo
CN109182250A (zh) * 2018-09-30 2019-01-11 山东省立医院 一种小鼠耳蜗毛细胞培养方法
WO2026043797A1 (en) * 2024-08-17 2026-02-26 Massachusetts Eye And Ear Infirmary Methods and compositions for prevention and treatment of hearing loss

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
US4637402A (en) 1980-04-28 1987-01-20 Adelman Roger A Method for quantitatively measuring a hearing defect
DE3169595D1 (en) 1980-11-10 1985-05-02 Gersonde Klaus Method of preparing lipid vesicles by ultrasonic treatment, the use of this method and apparatus for its application
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
EP0088046B1 (de) 1982-02-17 1987-12-09 Ciba-Geigy Ag Lipide in wässriger Phase
DE3218121A1 (de) 1982-05-14 1983-11-17 Leskovar, Peter, Dr.-Ing., 8000 München Arzneimittel zur tumorbehandlung
EP0102324A3 (de) 1982-07-29 1984-11-07 Ciba-Geigy Ag Lipide und Tenside in wässriger Phase
IL71991A (en) 1983-06-06 1994-05-30 Genentech Inc Preparation of human FGI and FGE in their processed form through recombinant AND tranology in prokaryotes
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
JPS607934A (ja) 1983-06-29 1985-01-16 Dai Ichi Seiyaku Co Ltd リポソ−ムの製造方法
DE3486459D1 (de) 1983-09-26 1997-12-11 Udo Dr Med Ehrenfeld Mittel und Erzeugnis für die Diagnose und Therapie von Tumoren sowie zur Behandlung von Schwächen der zelligen und humoralen Immunabwehr
EP0143949B1 (en) 1983-11-01 1988-10-12 TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION Pharmaceutical composition containing urokinase
AU598205B2 (en) 1985-08-22 1990-06-21 Gropep Pty Ltd Peptide analogues of mammalian insulin-like growth factor-1
US5439818A (en) 1985-09-12 1995-08-08 Scios Nova Inc. DNA encoding human recombinant basic fibroblast growth factor
SE8505922D0 (sv) 1985-12-13 1985-12-13 Kabigen Ab Construction of an igg binding protein to facilitate downstream processing using protein engineering
ES2007309T3 (es) 1987-04-23 1994-11-01 Monsanto Co Secrecion del factor de crecimiento insulinoide 1 en e.coli.
US4892538A (en) 1987-11-17 1990-01-09 Brown University Research Foundation In vivo delivery of neurotransmitters by implanted, encapsulated cells
US5470828A (en) 1987-12-24 1995-11-28 Gropep Pty. Ltd. Peptide analogs of insulin-like growth factor II
US5011472A (en) 1988-09-06 1991-04-30 Brown University Research Foundation Implantable delivery system for biological factors
US5352589A (en) 1988-09-16 1994-10-04 Farmitalia Carlo Erba S.R.L. Deletion mutant of basic fibroblast growth factor and production thereof
US5464943A (en) 1989-04-26 1995-11-07 Takeda Chemical Industries, Ltd. DNA encoding glycosylated FGF and production thereof
US5364839A (en) * 1990-06-18 1994-11-15 Genetics Institute, Inc. Osteoinductive pharmaceutical formulations
US5187151A (en) 1991-02-12 1993-02-16 Genentech, Inc. Use of binding protein with igf-i as an anabolic growth promoting agent
SG47470A1 (en) 1991-04-25 1998-04-17 Univ Brown Res Found Implantable biocompatible immunoisolatory vehicle for delivery of a selected therapeutic products
CA2089487A1 (en) * 1991-06-14 1992-12-15 Suk-Zu Song Collagen film drug delivery for proteins
JPH07504160A (ja) * 1991-11-27 1995-05-11 インスティチュート　オブ　モレキュラー　バイオロジー　インク 骨の再生
US5482929A (en) 1991-12-26 1996-01-09 Kaken Pharmaceutical Co., Ltd. Composition of stabilized fibroblast growth factor
US5546956A (en) 1992-04-04 1996-08-20 Medical Research Council Testing hearing
ES2174852T3 (es) * 1992-08-26 2002-11-16 Celtrix Pharma Metodo para el tratamiento sistemico de estados catabolicos y lesiones sistemicas de tejidos.
US5407913A (en) 1992-12-03 1995-04-18 Celtrix Pharmaceuticals, Inc. Method and composition for systemic treatment of tissue injury
ES2178654T3 (es) 1993-08-12 2003-01-01 Neurotech Sa Capsulas biocompatibles inmonoaisladoras que contienen celulas geneticamente alteradas para el suministro de moleculas biologicamente activas.
US6136785A (en) * 1995-08-08 2000-10-24 University Of Virginia Patent Foundation Protection from loss of sensory hair cells in the inner ear by administration of insulin-like growth factor and platelet derived growth factor

Also Published As

Publication number Publication date
ATE229815T1 (de) 2003-01-15
JP4191252B2 (ja) 2008-12-03
DE69718053D1 (de) 2003-01-30
DE69718053T2 (de) 2003-09-11
BR9712468A (pt) 1999-10-26
CN1251531A (zh) 2000-04-26
ZA979814B (en) 1999-04-30
WO1998019700A1 (en) 1998-05-14
IL129381A0 (en) 2000-02-17
US6593290B1 (en) 2003-07-15
JP2002514191A (ja) 2002-05-14
EP0948349B1 (en) 2002-12-18
AU7000698A (en) 1998-05-29
IL129381A (en) 2006-07-05
CN1313147C (zh) 2007-05-02
AU724988B2 (en) 2000-10-05
EP0948349A1 (en) 1999-10-13
CA2268331C (en) 2011-07-26
AR009603A1 (es) 2000-04-26
DK0948349T3 (da) 2003-04-07
CA2268331A1 (en) 1998-05-14

Similar Documents

Publication Publication Date Title
AR009603A1 (es) MÉTODO IN VITRO O EX VIVO PARA AUMENTAR EL NuMERO DE CÉLULAS PILOSAS DEL OIDO INTERNO EN UNA MUESTRA
ES2180597T4 (es) Aparato quirurgico asistido por tomografia de coherencia optica.
ES2147294T3 (es) Compuestos terapeuticos.
ES2176343T3 (es) Composiciones sanadoras de tratamiento de heridas causadas por el acne que contienen un piruvano, un antioxidante y una mezcla de acidos grasos.
ES2144980T1 (es) Metodos y composiciones para tratar la rinitis alergica y otros trastornos, empleando descarboetoxiloratadina.
ECSP941122A (es) Derivados de 5-arilindoles
ES2170141T3 (es) 4-aminoderivados del acido micofenolico con actividad inmunosupresora.
DE60020370D1 (de) Flüssigkeitsabgabevorrichtung
ES2060775T3 (es) Egf para la prevencion de daños en tejidos despues de un episodio isquemico.
ES2170938T3 (es) Utilizacion del factor neurotrofico derivado de celulas gliales (gdnf) para el tratamiento de las deficiencias auditivas.
CU23226B7 (es) COMPOSICIONES ANALGéSICAS QUE COMPRENDEN COMPUESTOS ANTI-EPILéPTICOS Y ANTINFLAMATORIOS NO ESTEROIDEOS
PT1086702E (pt) Neurotoxinas pre-sinapticas para tratamento da dor de cabeca devida a enxaqueca
PT1173197E (pt) Intervencao metabolica com glp-1, para melhorar a funcao do tecido isquemico e reperfundido
DK1296652T3 (da) Topiske farmaceutiske formuleringer og behandlingsfremgangsmåder
MX9305444A (es) Derivados de rodanina como agentes hipoglucemicos y para el tratamiento de la enfermedad de alzheimer, composiciones farmaceuticas que los contienen y procedimiento para su preparacion.
CL2010000383A1 (es) Esteres y amida de acidos carboxilicos que contienen un agente anti-inflamatorio no esteroidal; composicion farmaceutica: y su uso como inhibidores de 5-lipoxigenasa para prevenir o aliviar edema de tejidos, inflamacion y congestion de la conjuntiva, de la nubosidad de la cornea y daños a tejidos oftalmicos (divisional sol. 3109-99).
PA8559501A1 (es) Formulaciones farmaceuticas de 5,7,14-triazatetraciclo[10.3.1.02,11.04,9]-hexadeca-2(11),3,5,7,9-pentaeno
AR023346A1 (es) Compuestos derivados biciclicos substituidos utiles como agentes contra el cancer, uso de los mismos para preparar un medicamento, composicionesfarmaceuticas y procedimiento de preparacion de los compuestos
AR015360A1 (es) Proceso para la manufactura de una composicion farmaceutica para reducir o prevenir los efectos de la inflamacion; dicha composicion farmaceutica y unelemento para aplicar la composicion farmaceutica en dicho proceso
ES2115727T3 (es) Esponja para la cornea.
ECSP077349A (es) Nuevos derivados de sulfonamida como moduladores del receptor de glucocorticoides para el tratamiento de enfermedades inflamatorias
ES2227684T3 (es) Albumina como ingrediente activo para el tratamiento de lesiones conjuntivas y de la cornea y del ojo seco.
MX9200894A (es) Composiciones terapeuticas para proteger y resucitar las celulas de mamiferos y metodos para preparar y usar las mismas.
AR037881A1 (es) Uso de derivados de oxindol
ES2168359T3 (es) Acido micofenolico 6-sustituido y derivados con actividad inmunosupresora.